Bank Of America Upgrades Sarepta Therapeutics On 'Increased Conviction' Of Drug Approval
February 17, 2015 at 13:54 PM EST
Bank of America upgraded Sarepta Therapeutics Inc (NASDAQ: SRPT) from Neutral to Buy on Tuesday and raised its price target from $19 ...